Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1985-7-24
|
| pubmed:abstractText |
The antiarrhythmic effects of Encainide in acute intravenous and long-term oral therapy were investigated in 10 patients suffering from chronic atrial ectopic beats previously non-responsive to conventional therapy. The efficacy of Encainide was assessed by 24-hour ECG monitoring during the acute i.v. application and in 4 week intervals over a period of 4 to 6 months. Plasma concentrations of Encainide and the O-demethyl- (ODE) and 3-methoxy-O-demethyl metabolites (3-MODE) were determined after i.v. administration and during oral therapy. A significant reduction of arrhythmias by 76% was found after 1.0 mg/kg Encainide given intravenously. Atrial ectopic beats with bundle branch block QRS-morphology were reduced by more than 90% after only 0.5 mg/kg. During long-term oral therapy 6 of the 9 patients were treated successfully. Following i.v. administration Encainide-plasma concentrations rapidly decreased with a half life of approximately 75 min in the final distribution phase. During oral therapy Encainide levels were not detectable under steady state conditions 4 to 6 hours after the last dose, or they were only minimal, but the average concentrations of ODE and 3-MODE were 71.3 +/- 21.3 and 75.6 +/- 13.5 ng/ml. Encainide increased PR interval and QRS duration significantly. QT-interval changed as a result of the QRS-prolongation. Encainide was well tolerated during acute and chronic therapy. No severe side effects were seen, except in one case, in which dose reduction by 50% was necessary because of blurred vision.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
ger
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0300-5860
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
74
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
220-7
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:2408392-Administration, Oral,
pubmed-meshheading:2408392-Adult,
pubmed-meshheading:2408392-Aged,
pubmed-meshheading:2408392-Anilides,
pubmed-meshheading:2408392-Anti-Arrhythmia Agents,
pubmed-meshheading:2408392-Cardiac Complexes, Premature,
pubmed-meshheading:2408392-Dose-Response Relationship, Drug,
pubmed-meshheading:2408392-Electrocardiography,
pubmed-meshheading:2408392-Encainide,
pubmed-meshheading:2408392-Female,
pubmed-meshheading:2408392-Half-Life,
pubmed-meshheading:2408392-Heart Atria,
pubmed-meshheading:2408392-Heart Rate,
pubmed-meshheading:2408392-Humans,
pubmed-meshheading:2408392-Infusions, Parenteral,
pubmed-meshheading:2408392-Long-Term Care,
pubmed-meshheading:2408392-Male,
pubmed-meshheading:2408392-Metabolic Clearance Rate,
pubmed-meshheading:2408392-Middle Aged
|
| pubmed:year |
1985
|
| pubmed:articleTitle |
[Acute and long-term antiarrhythmia effect of encainide in chronic atrial extrasystole].
|
| pubmed:publicationType |
Journal Article,
English Abstract
|